share_log

HC Wainwright & Co. Reiterates Buy on Denali Therapeutics, Maintains $95 Price Target

HC Wainwright & Co. Reiterates Buy on Denali Therapeutics, Maintains $95 Price Target

HC Wainwright & Co.重申买入Denali Therapeutics,维持95美元的目标股价
Benzinga ·  05/08 09:11

HC Wainwright & Co. analyst Andrew Fein reiterates Denali Therapeutics (NASDAQ:DNLI) with a Buy and maintains $95 price target.

HC Wainwright & Co. 分析师安德鲁·费恩重申Denali Therapeutics(纳斯达克股票代码:DNLI)的买入并维持95美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发